Prostate cancer with Gleason pattern 4 low mag

US-based clinical stage biopharmaceutical firm Arno Therapeutics (ARNI) has started enrolling patients in a Phase I/II trial (NCT02049190) assessing its oral, anti-progestin hormone blocker ‘onapristone’ in men with advanced castration-resistant prostate cancer (CRPC) after failure of abiraterone or enzalutamide.

In previous Phase II clinical trials, onapristone has shown to exhibit anti-tumour activity in patients with breast cancer.

The pre-clinical testing has showed that onapristone had blocked the activation of the progesterone receptor (PR), which is believed to be a mechanism that inhibits the growth of APR-driven breast, endometrial and other tumours.

The company said that tests for the activated form of the progesterone receptor (APR) have the potential to function as a biomarker of anti-progestin activity, as detected by a companion diagnostic under development.

Enrolment of patients in the randomised, open-label Phase I/II trial follows approval of an Investigational Medicinal Product Dossier from the UK Health Authority, Medicines and Healthcare products Regulatory Agency (MHRA), ethics committee authorisation and subsequent site authorisation.

Arno Therapeutics president and chief executive officer Glenn Mattes said globally, prostate cancer is the second most common cancer in men, and the fifth leading cause of death from cancer in men, with an estimated 1.1 million new cases diagnosed and 307,000 deaths during 2012 alone, according to the International Agency for Research on Cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"These numbers are staggering, and our ultimate goal is to evaluate onapristone in the subset of advanced CRPC patients who are more likely to respond to this personalised treatment, for which there is an immense unmet medical need," Mattes said.

"The trial marks Arno’s second Phase I study actively enrolling this year and we are excited by the momentum generated thus far."

The Phase I/II trial, designed to assess the safety and anti-cancer activity of onapristone in the select patient population, is being carried out at the Institute of Cancer Research, London, and the Royal Marsden NHS Foundation Trust in the UK.

A total of 60 patients will be enrolled in the trial, which additional sites are planned for in the UK.

The company has engaged Biotrial, a drug evaluation and pharmacology research company, as its contract research organisation (CRO) for the Phase I/II trial.

The trial will evaluate onapristone in extended-release tablet formulations in up to five dose levels (10mg-50mg BID) in patients with advanced CRPC where PR may be contributing to tumour progression.

Patients in the trial will be evaluated for whether their tumours express APR, which may help identify patients who are more likely to respond to onapristone.

A second group of patients will be included at the recommended Phase II dose to gain additional understanding of the onapristone safety profile and potential anti-cancer activity.

Image: Micrograph of prostate adenocarcinoma, acinar type, the most common type of prostate cancer. Photo: courtesy of Nephron.

Frequently asked questions

  • 1. How are Medical Devices companies using robotics?

    Medical Devices companies are using robotics to improve the standard of care and help humans perform tasks they may not have been able to do. The two main types of medical robots are surgical robots and care robots. Other types of robots could be used in a medical context, including exoskeletons. Cleaning and maintenance robots are used in hospitals and care homes, but are not explicitly designed for medical use.

  • 2. How does robotics impact the Medical Devices industry?

    Robotics is having a significant impact on the Medical Devices industry. The use of cloud computing and AI enables robots to collaborate and access huge amounts of data uninterruptedly. Automation is key to improving productivity. As countries and companies recover from the pandemic, interest in robotics will increase. Robust growth is expected in medical robotics in the next decade.

  • 3. Who are the top robotics adopters in Medical Devices?

    The top robotics adopters in Medical Devices are Intuitive Surgical, Medtronic, Johnson & Johnson, Stryker, Zimmer Biomet, and Cyberdyne. These companies are leading the way in the development and adoption of surgical robots and care robots.

  • 4. Who are the leading providers of robotics in the Medical Devices industry?

    The leading providers of robotics in the Medical Devices industry include ABB, Cognex, Microsoft, Rockwell Automation, Google, Amazon, Amazon, Preferred Networks, FANUC, C2RO, Midea (KUKA), and Cisco.

  • 5. How does investment in robotics help Medical Devices companies?

    Investment in robotics can lead to improved productivity and efficiency, as well as better patient outcomes.

  • 6. What are the challenges with adoption of robotics in Medical Devices?

    The challenges with adoption of robotics in Foodservice include high initial costs, lack of skilled labor to operate and maintain the robots, and concerns about the impact on employment. There are also regulatory challenges.

  • 7. What is the projected market size of robotics in Medical Devices?

    According to GlobalData forecasts, the total surgical robotics market will have grown at a strong compound annual growth rate (CAGR) of 8.5% from 2020 to 2030, bolstered by the coming marriage of artificial intelligence (AI) and robotics within medical devices.

  • 8. Who are the leading specialist robotics vendors in Medical Devices?

    The leading specialist robotics vendors in Medical Devices include Harmonic Drive, Omron, TE Connectivity, Nabtesco, Keyence, and Honeywell. These companies provide precision mechanical parts and semiconductors that are essential components of medical robots.

  • 9. What are the components of the robotics value chain?

    The components of the robotics value chain include robot manufacturing, hardware components (such as precision mechanical parts and semiconductors), software components (such as robotic intelligence and cloud robotics), and robotics as a service.